138 related articles for article (PubMed ID: 10537340)
1. Phase I study of direct intralesional gene transfer of HLA-B7 into metastatic renal carcinoma lesions.
Rini BI; Selk LM; Vogelzang NJ
Clin Cancer Res; 1999 Oct; 5(10):2766-72. PubMed ID: 10537340
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of direct intralesional gene transfer of allovectin-7, an HLA-B7/beta2-microglobulin DNA-liposome complex, in patients with metastatic melanoma.
Stopeck AT; Jones A; Hersh EM; Thompson JA; Finucane DM; Gutheil JC; Gonzalez R
Clin Cancer Res; 2001 Aug; 7(8):2285-91. PubMed ID: 11489803
[TBL] [Abstract][Full Text] [Related]
3. Gene therapy for head and neck cancer.
Gleich LL
Laryngoscope; 2000 May; 110(5 Pt 1):708-26. PubMed ID: 10807351
[TBL] [Abstract][Full Text] [Related]
4. Clinical experience with HLA-B7 plasmid DNA/lipid complex in advanced squamous cell carcinoma of the head and neck.
Gleich LL; Gluckman JL; Nemunaitis J; Suen JY; Hanna E; Wolf GT; Coltrera MD; Villaret DB; Wagman L; Castro D; Gapany M; Carroll W; Gillespie D; Selk LM
Arch Otolaryngol Head Neck Surg; 2001 Jul; 127(7):775-9. PubMed ID: 11448348
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of immunotherapy of hepatic metastases of colorectal carcinoma by direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7.
Rubin J; Galanis E; Pitot HC; Richardson RL; Burch PA; Charboneau JW; Reading CC; Lewis BD; Stahl S; Akporiaye ET; Harris DT
Gene Ther; 1997 May; 4(5):419-25. PubMed ID: 9274718
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7, in patients with metastatic melanoma.
Stopeck AT; Hersh EM; Akporiaye ET; Harris DT; Grogan T; Unger E; Warneke J; Schluter SF; Stahl S
J Clin Oncol; 1997 Jan; 15(1):341-9. PubMed ID: 8996161
[TBL] [Abstract][Full Text] [Related]
7. Human gene therapy for melanoma: CT-guided interstitial injection.
Waddill W; Wright W; Unger E; Stopeck A; Akporiaye E; Harris D; Grogan T; Schluter S; Hersh E; Stahl S
AJR Am J Roentgenol; 1997 Jul; 169(1):63-7. PubMed ID: 9207502
[TBL] [Abstract][Full Text] [Related]
8. Phase 2 trial of Allovectin-7 in advanced metastatic melanoma.
Gonzalez R; Hutchins L; Nemunaitis J; Atkins M; Schwarzenberger PO
Melanoma Res; 2006 Dec; 16(6):521-6. PubMed ID: 17119453
[TBL] [Abstract][Full Text] [Related]
9. Technology evaluation: Allovectin-7, Vical.
Galanis E
Curr Opin Mol Ther; 2002 Feb; 4(1):80-7. PubMed ID: 11883699
[TBL] [Abstract][Full Text] [Related]
10. Intratumoral administration of a 1,2-dimyristyloxypropyl-3- dimethylhydroxyethyl ammonium bromide/dioleoylphosphatidylethanolamine formulation of the human interleukin-2 gene in the treatment of metastatic renal cell carcinoma.
Galanis E; Burch PA; Richardson RL; Lewis B; Pitot HC; Frytak S; Spier C; Akporiaye ET; Peethambaram PP; Kaur JS; Okuno SH; Unni KK; Rubin J
Cancer; 2004 Dec; 101(11):2557-66. PubMed ID: 15517589
[TBL] [Abstract][Full Text] [Related]
11. Velimogene aliplasmid.
Soares HP; Lutzky J
Expert Opin Biol Ther; 2010 May; 10(5):841-51. PubMed ID: 20367461
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of the intratumoral administration of recombinant canarypox viruses expressing B7.1 and interleukin 12 in patients with metastatic melanoma.
Triozzi PL; Allen KO; Carlisle RR; Craig M; LoBuglio AF; Conry RM
Clin Cancer Res; 2005 Jun; 11(11):4168-75. PubMed ID: 15930353
[TBL] [Abstract][Full Text] [Related]
13. Immunologic therapy targeting metastatic melanoma: allovectin-7.
Chowdhery R; Gonzalez R
Immunotherapy; 2011 Jan; 3(1):17-21. PubMed ID: 21174553
[TBL] [Abstract][Full Text] [Related]
14. A phase 2 study of high-dose Allovectin-7 in patients with advanced metastatic melanoma.
Bedikian AY; Richards J; Kharkevitch D; Atkins MB; Whitman E; Gonzalez R
Melanoma Res; 2010 Jun; 20(3):218-26. PubMed ID: 20354459
[TBL] [Abstract][Full Text] [Related]
15. Novel jet-injection technology for nonviral intratumoral gene transfer in patients with melanoma and breast cancer.
Walther W; Siegel R; Kobelt D; Knösel T; Dietel M; Bembenek A; Aumann J; Schleef M; Baier R; Stein U; Schlag PM
Clin Cancer Res; 2008 Nov; 14(22):7545-53. PubMed ID: 19010873
[TBL] [Abstract][Full Text] [Related]
16. Major histocompatibility gene therapy: the importance of haplotype and beta 2-microglobulin.
Salamone FN; Gleich LL; Li YQ; Stambrook PJ
Laryngoscope; 2004 Apr; 114(4):612-5. PubMed ID: 15064612
[TBL] [Abstract][Full Text] [Related]
17. Intramuscular gene transfer of soluble B7.1/IgG(1) fusion cDNA induces potent antitumor immunity as an adjuvant for DNA vaccination.
Zhou ZF; Peretz Y; Chang Y; Miao DS; Li X; Prud'homme GJ
Cancer Gene Ther; 2003 Jun; 10(6):491-9. PubMed ID: 12768195
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of HLA-B7/beta-2 microglobulin plasmid DNA/lipid complex (Allovectin-7) in patients with metastatic melanoma.
Bergen M; Chen R; Gonzalez R
Expert Opin Biol Ther; 2003 Apr; 3(2):377-84. PubMed ID: 12662150
[TBL] [Abstract][Full Text] [Related]
19. Superior antitumor in vitro responses of allogeneic matched sibling compared with autologous patient CD8+ T cells.
Kausche S; Wehler T; Schnürer E; Lennerz V; Brenner W; Melchior S; Gröne M; Nonn M; Strand S; Meyer R; Ranieri E; Huber C; Falk CS; Herr W
Cancer Res; 2006 Dec; 66(23):11447-54. PubMed ID: 17145892
[TBL] [Abstract][Full Text] [Related]
20. Alloantigen gene therapy for squamous cell carcinoma of the head and neck: results of a phase-1 trial.
Gleich LL; Gluckman JL; Armstrong S; Biddinger PW; Miller MA; Balakrishnan K; Wilson KM; Saavedra HI; Stambrook PJ
Arch Otolaryngol Head Neck Surg; 1998 Oct; 124(10):1097-104. PubMed ID: 9776187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
